# Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

> **NCT05963087** · NA · NOT_YET_RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab Dabrafenib Tislelizumab

## Key facts

- **NCT ID:** NCT05963087
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08
- **Primary completion:** 2025-02
- **Final completion:** 2026-06
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963087, "Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05963087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*